文献速递胸部肿瘤

Ⅰ期非小细胞肺癌立体定向放疗与手术的纵向健康效用差异

Differences in Longitudinal Health Utility between Stereotactic Body Radiation Therapy and Surgery in Stage I Non-Small Cell Lung Cancer.
PubMed 文献 · J Thorac Oncol · 2018-01-31

本研究汇总荷兰两家医院的前瞻性数据,比较Ⅰ期非小细胞肺癌患者接受立体定向放疗(SBRT)与手术切除后第一年内(无复发前)的纵向健康效用。采用倾向性评分匹配和纵向混合模型分析,校正ECOG评分、性别和年龄后,两组1年平均健康效用差异为0.026(95%CI:0.028-0.080),差异随时间缩小。结论认为SBRT是早期NSCLC的等效治疗选择,但成本效果比尚待确定。

要点

  • 校正混杂因素后,SBRT与手术的1年平均健康效用差异为0.026(95%CI:0.028-0.080),无统计学显著性。
  • 健康效用差异随时间推移而缩小。
  • SBRT可作为早期NSCLC的等效治疗选择,成本效果比尚待确定。

核心结论

  • Ⅰ期NSCLC患者接受手术与SBRT后第一年内健康效用差异小且无统计学显著性。
  • 现有证据支持SBRT是早期NSCLC的等效治疗选择。
  • 两种治疗的成本效果比较仍需进一步研究确定。

研究设计与样本

  • 汇总荷兰两家大型医院的前瞻性数据库,纳入接受SBRT或手术治疗的Ⅰ期NSCLC患者。
  • 使用QLQ-C30问卷在基线及治疗后3、6、12个月测量生活质量,并通过映射算法计算EQ-5D健康效用。
  • 采用倾向性评分匹配校正选择偏倚,并用纵向混合模型估计匹配患者的治疗效果。

主要发现

  • 校正ECOG评分、性别和年龄后,SBRT组与手术组1年平均健康效用差异为0.026(95%CI:0.028-0.080)。
  • 两组健康效用差异随时间推移而减小。

临床怎么用

  • 临床决策时可参考本研究表明SBRT与手术在首年健康效用上差异无统计学显著性。
  • 需结合患者偏好和个体情况选择SBRT或手术,并关注长期成本效果。

局限性

  • 本研究为回顾性汇总前瞻性数据库,可能存在未校正的选择偏倚。
  • 健康效用通过QLQ-C30映射算法间接计算,非直接测量。
  • 仅分析治疗前12个月且无复发患者的数据,长期效用未知。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: There is an ongoing debate on the optimal treatment for stage I NSCLC, with increasing evidence for comparable health outcomes after surgery and stereotactic body radiation therapy (SBRT). For clinical decision making, the experienced quality of life, summarized as health utility, is of importance to choosing between treatments. In this study, we evaluated differences in longitudinal health utility in stage I NSCLC in the first year after surgical resection versus after SBRT before any recurrence of disease. We also assessed the impact of potential prognostic variables on health utility. METHODS: Prospectively collected databases containing data on patients with stage I NSCLC treated with either SBRT or surgery were pooled from two large hospitals in the Netherlands. Quality of life data were measured by the Quality of Life Questionnaire-Core 30 questionnaire at baseline and 3, 6, and 12 months after treatment. Health utility (measured using the European Quality of Life Five-Dimension questionnaire) was calculated from the Quality of Life Questionnaire-Core 30 questionnaire by using a mapping algorithm. Propensity score matching was used to adjust for selection bias. Treatment effects were estimated for the matched patients by using a longitudinal mixed model approach. RESULTS: After correction for Eastern Cooperative Oncology Group score, sex, and age, the difference in 1-year averaged health utility between the SBRT and surgery groups was 0.026 (95% confidence interval: 0.028-0.080). Differences in health utility decreased over time. CONCLUSIONS: A small but not statistically significant difference in health utility was found between patients with stage I NSCLC treated with surgery and those treated with SBRT. Current analysis strengthens existing evidence that SBRT is an equivalent treatment option for early-stage NSCLC. Comparative cost-effectiveness remains to be determined.

来源:J Thorac Oncol,查看原文。版权归原作者所有。

引用

  1. Wolff HB, Alberts L, Kastelijn EA, et al. Differences in Longitudinal Health Utility between Stereotactic Body Radiation Therapy and Surgery in Stage I Non-Small Cell Lung Cancer. J Thorac Oncol. 2018. PMID: 29391288. doi:10.1016/j.jtho.2018.01.021

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。